Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) passed the generic drug quality and efficacy consistency evaluation for its cefuroxime sodium for injection, according to a Tuesday filing with the Shanghai bourse.
The pharmaceutical company has invested about 5.0 million yuan in research and development for the antibiotic drug.
Guangzhou Baiyunshan Pharmaceutical also secured the State Drug Administration's drug supplementary application approval for its general factory.
Shares of the company were down 1% in recent trade.
Price (HKD): $29.79, Change: $-0.29, Percent Change: -0.96%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments